Clinical Trials on Urinary Bladder Neoplasm in Portugal

Total 1180 results

Pfizer

Completed

Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder

Urinary Bladder, Overactive

Portugal
Vensica Therapeutics Ltd.

Completed

Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder

Overactive Bladder

Czechia, Portugal
European Organisation for Research and Treatment...

Completed

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, United Kingdom, Italy, Portugal, Turkey
Vensica Therapeutics Ltd.
Blueclinical, Ltd.

Completed

Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects (XAVIER)

Overactive Bladder

Portugal
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

Neoplasm Metastasis | Urinary Bladder Neoplasm

United States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
European Organisation for Research and Treatment...

Completed

Surgery and BCG in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, France, Austria, United Kingdom, Israel, Italy, Turkey, Greece, Portugal, Romania
Sanofi

Completed

SSR240600C Treatment in Women With Overactive Bladder (BILADY)

Overactive Bladder

France, Germany, Netherlands, Portugal, Czech Republic, United States, Canada
University of Oxford
King's College London; Bayer; Boston Children's Hospital; Queen Mary University... and other collaborators

Completed

Translational Research in Pelvic Pain (TRiPP)

Chronic Pain | Endometriosis | Bladder Pain Syndrome

United Kingdom, Portugal
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Portugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Bladder Cancer

United States, France, Belgium, Korea, Republic of, United Kingdom, Czechia, Austria, Canada, Denmark, Greece, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, Poland, Hungary, Switzerland, Japan, Taiwan, Australia, Norway, Germa... and more
Sanofi

Completed

Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction (ALFACHIN)

Neurogenic Urinary Bladder

United States, France, Canada, Poland, Germany, Portugal, Spain, Turkey, Bulgaria, Estonia, India, Malaysia, Philippines, Russian Federation, Serbia, Singapore, Slovakia, Taiwan
Bayer

Completed

Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) (OVADER)

Overactive Bladder

Austria, Singapore, New Zealand, Australia, Portugal, Czechia, Poland, Germany, Sweden
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Netherlands, Portugal, Australia, Russian Federation, Ukraine
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Allergan

Completed

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Overactive Bladder

Poland, United Kingdom, Portugal, South Africa, Ukraine, Australia, Netherlands, Canada, Singapore, Russian Federation, Germany, Brazil, Austria, Slovakia, Czechia, United States, Taiwan, Italy, France, Belgium, Spain, New Zealand
Allergan

Completed

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

Multiple Sclerosis | Urinary Incontinence | Neurogenic Bladder

France, Poland, Portugal, Belgium, Canada, Russian Federation, Czechia, United States
Bayer

Completed

A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

Overactive Bladder | Detrusor Overactivity

Spain, Belgium, Canada, Netherlands, Switzerland, Russian Federation, Germany, Israel, Hungary, Portugal, France, Poland, Czech Republic
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Urinary Bladder Neoplasms

United States, Australia, Czechia, Estonia, France, Guatemala, Hungary, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Poland, Portugal, Puerto Rico, Romania, Spain, Taiwan, Turkey, Ukraine, United Kingdom, Denmark, ... and more
Astellas Pharma Europe B.V.

Completed

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) (AMARANTH)

Pain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder Disease

Belgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain
Astellas Pharma Inc

Completed

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms (SUNRISE)

Urinary Bladder, Overactive

France, United Kingdom, Belgium, Germany, Spain, Portugal, Greece, Russian Federation, Czech Republic, Poland, Hungary, Italy, Slovakia, Egypt
Fundacao Champalimaud

Completed

Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer (PROSINT)

PROSTATE CANCER

Portugal
Fundacao Champalimaud

Recruiting

Phase II Study of Single-Dose Image-Guided Radiotherapy (SDRT) for Prostate Cancer (PROSINT II)

Prostate Cancer

Portugal
João Firmino Domingues Barbosa Machado
Universidade do Porto

Completed

Stepwise Strategy to Improve CANcer Screening Adherence: Cervical Cancer (SCAN-CC)

Reminder Systems | Uterine Cervical Neoplasm | Mass Screening | Early Detection of Cancer | Text Message

Portugal
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

Urinary Bladder Neoplasms

Taiwan, Korea, Republic of, Austria, Germany, China, United States, Greece, Italy, Argentina, Belgium, Brazil, Russian Federation, Spain, Canada, Czechia, France, Mexico, Japan, Poland, Portugal, Australia, Hungary, India, Ukraine, Turkey
Pfizer

Completed

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (SOFIA)

Urinary Bladder, Overactive

Portugal, Spain, Turkey, Finland, Germany, Norway, Sweden, Slovakia, Italy, Austria, United Kingdom, Belgium, Denmark, Israel, Switzerland
Fundacao Champalimaud

Unknown

Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer

Metastatic Prostate Cancer | Prostate Adenocarcinoma

Portugal
Fundacao Champalimaud

Unknown

Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer

Adenocarcinoma of the Prostate

Portugal
Hospital de Santa Maria, Portugal

Completed

A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-core Biopsy Scheme

Prostate Cancer

Portugal
Hospital de Santa Maria, Portugal
Centro Hospitalar Lisboa Norte; Instituto de Medicina Molecular João Lobo Antunes

Completed

Circulating Tumor Cell Reducing No-touch Nephrectomy (CITO-CERENE)

Renal Cell Carcinoma | Circulating Tumor Cell

Portugal
Universidade do Porto
Horizon 2020 - European Commission

Recruiting

Testing an e-Health Intervention for Prostate Cancer Survivors' Mental and Sexual Health

Prostate Cancer

Portugal
Fundacao Champalimaud

Unknown

Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy (SHARP)

SBRT | Adjuvant Radiotherapy | Prostate Cancer Adenocarcinoma | Salvage Radiotherapy | IGRT | Urethral Sparing

Portugal
BioProtect

Completed

Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients (CLP-10095)

Prostate Cancer

Poland, Portugal
Fundacao Champalimaud

Completed

POSE - POs Surgery Endometrial Cancer (POSE)

Endometrial Cancer

Portugal
Fundacao Champalimaud

Recruiting

VIBE - Virtual Image Guided Brachytherapy Emulation for Locally Advanced Cervical Cancer (LACC) (VIBE)

Cervical Cancer

Portugal
Instituto Politécnico de Leiria

Completed

Home-based Exercise Training for Lung Cancer Patients Awaiting Surgery

Lung Neoplasm

Portugal
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Universidade do Porto

Unknown

Non-curative ESDs: Assessing the Rates and Risk Factors for Residual Neoplasia (NC-ESD)

Colorectal Neoplasms | Esophageal Neoplasms | Gastric Neoplasm

Portugal
Hospital Sao Joao

Completed

Radiofrequency Ablation for the Treatment of Gastric Dysplasia

Gastric Dysplasia | Neoplasia

Portugal
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
Instituto Politécnico de Leiria

Completed

Home-based Preoperative Exercise Training for Lung Cancer Patients Undergoing Surgery

Lung Neoplasm

Portugal
Portuguese Oncology Institute, Coimbra

Completed

Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars

Colorectal Cancer | Recurrence, Local Neoplasm

Portugal
Associacao de Investigacao de Cuidados de Suporte...
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.; University Institute... and other collaborators

Unknown

Walking Football as a Supportive Medicine for Patients With Prostate Cancer

Prostate Cancer | Androgen Deprivation Therapy

Portugal
Centro Hospitalar De São João, E.P.E.

Completed

Comparison Between a Telerehabilitation Program for Urinary Incontinence Versus a Conventional Face-to-face Program

Covid19 | Stress Urinary Incontinence | Pelvic Floor Muscle Weakness | Incontinence, Urinary

Portugal

Clinical Trials on Urinary Bladder Neoplasm in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations